Entera Bio ENTX 深 滬
等待開盤 11-04 09:30:00 美东时间
3.05
-0.040
-1.29%
華盛通- 最 高3.12
- 今 開3.06
- 成交量 13.69万股
- 最 低 2.99
- 昨 收 3.09
- 總市值 5.30亿
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 0.91
- 委 比 -95.12%
- 總股本 1.74亿
- 歷史最高 10.16
- 量 比 0.60
- 振 幅 4.21%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entera Bio收跌3.44%，成交额102.26万美元
11月3日，Entera Bio（ENTX）收跌3.44%，报3.09美元，成交额102.26万美元，市值5.37亿美元。 行情数据 • 开盘价：3.19美元...
11-03 07:02
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
Entera Bio Ltd. announced the appointment of Juan Camilo Arjona Ferreira, M.D., as a Board member, effective December 1, 2026. Dr. Arjona Ferreira, a seasoned clinical leader with over 20 years of experience in women’s health and regulatory affairs, succeeds Haya Taitel. His expertise aligns with Entera’s focus on developing oral peptide therapies, particularly for osteoporosis and hypoparathyroidism. Dr. Arjona Ferreira currently leads Organon’s...
10-27 12:00
Entera Bio收跌2.05%，成交额66.35万美元
10月27日，Entera Bio（ENTX）收跌2.05%，报2.86美元，成交额66.35万美元，市值4.97亿美元。 行情数据 • 开盘价：2.9美元 ...
10-27 06:07
Entera Bio收跌3.25%，成交额154.77万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:11
Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These findings support the potential benefit of EB613 in postmenopausal women with osteoporo...
10-13 19:02
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. With over 35 years of experience in global commercial leadership, Hamill joins Entera as it advances its late-stage clinical trials and prepares for the commercialization of EB613, an oral therapy for osteoporosis. Hamill previously served at Gilead Sciences and Amgen, leading multi-billion dollar franchises. Her expertise is expected ...
10-06 12:00
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Short interest data from late September 2026 highlights deeply divided investor sentiment across small-cap healthcare stocks (market capitalizations up to $2B). Heavy bearish bets remain concentrated ...
10-02 22:15
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
09-18 21:19
